Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

L.A. McKeown

December 23, 2024

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

L.A. McKeown

December 21, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

Todd Neale

December 23, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2019

Shelley Wood

May 01, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

FDA’s ‘Medical Device Safety Action Plan’ Focuses on Product Life Cycles and Preventing Cyberattacks

L.A. McKeown

April 20, 2018

Advertisement

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

FDA Approves Triple Therapy Polypill for High Blood Pressure

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

FDA Approves Two Additional Indications for Rivaroxaban in Children

British Medical Groups Express Concern About Inclisiran Rollout

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Inclisiran Approved in Europe for Lowering LDL Cholesterol

FDA Approves Two Generic Versions of Apixaban

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

TCTMD’s Top 10 Most Popular Stories for April 2019

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

FDA’s ‘Medical Device Safety Action Plan’ Focuses on Product Life Cycles and Preventing Cyberattacks

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content